CO6180448A2 - Gel conteniendo pirfenidona - Google Patents
Gel conteniendo pirfenidonaInfo
- Publication number
- CO6180448A2 CO6180448A2 CO10015040A CO10015040A CO6180448A2 CO 6180448 A2 CO6180448 A2 CO 6180448A2 CO 10015040 A CO10015040 A CO 10015040A CO 10015040 A CO10015040 A CO 10015040A CO 6180448 A2 CO6180448 A2 CO 6180448A2
- Authority
- CO
- Colombia
- Prior art keywords
- solubilizer
- pirfenidone
- agent
- neutralizing agent
- preservative
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Pyridine Compounds (AREA)
Abstract
La presente invención describe una composición de gel conteniendo Pirfenidona, que ofrece ventajas sobre otras formas farmacéuticas de administración cutánea conocidas en el estado de la técnica, que es útil en el tratamiento para la restauración de los tejidos con lesiones fibróticas y para la prevención de lesiones fibróticas. 1.- Una composición de gel conteniendo Pirfenidone caracterizada porque comprende del 2 al 12% de Pirfenidona, de 0.4 a 1.2% de un agente de viscosidad, de 10 al 30% de un solubizante, del 5 al 15% de un solubilizante no iónico, de 0.2 al 1% de un conservador, del 0.4 al 1.2% de un agente neutralizante y el resto de agua purificada. 2.- La composición de la reivindicación 1, caracterizada porque comprende Pirfenidona 8%; 0.5 de un agente de viscosidad, 20% de un solubizante, 11.5% de un solubilizante no iónico, 0.5% de un conservador, 0.5% de un agente neutralizante y el resto de agua purificada. 3.- La composición de la reivindicación 1, caracterizada porque el agente de viscosidad se selecciona de Carbomero 940 (MR); Ultrex 10(MR), derivados de celulosa; gomas; polioxameros; el solubilizante se selecciona de metil pirrolidona; alcohol etílico y propilenglicol; el conservador se selecciona del grupo que consiste de diazolidinilurea, iodopropinilbutilcarbamato; metilparabeno, propilparabeno y mezclas de los mismos; el agente neutralizante es seleccionado del grupo de aminas alifáticas primaria, secundarias o terciarias del tipo de la mono-, di- y trietanolamina, y de los hidróxidos de metales alcalinos, como el hidróxido de sodio. 4.- La composición de la reivindicación 1, caracterizada porque el agente de viscosidad es Carbomero 940 (MR); el solubilizante es N-metilpirrolidona; el conservador es diazolidinilurea y iodopropinilbutilcarbamato; el agente neutralizante es trietanoalamina.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2007009796A MX2007009796A (es) | 2007-08-14 | 2007-08-14 | Gel conteniendo pirfenidona. |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6180448A2 true CO6180448A2 (es) | 2010-07-19 |
Family
ID=40350871
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO10015040A CO6180448A2 (es) | 2007-08-14 | 2010-02-11 | Gel conteniendo pirfenidona |
Country Status (14)
Country | Link |
---|---|
US (6) | US8492412B2 (es) |
EP (1) | EP2177220B1 (es) |
JP (1) | JP5542053B2 (es) |
KR (1) | KR101235968B1 (es) |
CN (2) | CN104771355A (es) |
BR (1) | BRPI0815203B8 (es) |
CA (1) | CA2696335C (es) |
CO (1) | CO6180448A2 (es) |
EC (1) | ECSP109960A (es) |
HK (1) | HK1211464A1 (es) |
MX (1) | MX2007009796A (es) |
SG (1) | SG183732A1 (es) |
WO (1) | WO2009022899A1 (es) |
ZA (1) | ZA201000918B (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2007009796A (es) | 2007-08-14 | 2009-02-25 | Cell Therapy And Technology S | Gel conteniendo pirfenidona. |
EP2296653B1 (en) | 2008-06-03 | 2016-01-27 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
CN101972225A (zh) * | 2010-10-13 | 2011-02-16 | 北京诚创康韵医药科技有限公司 | 一种含吡非尼酮的凝胶组合物 |
US10105356B2 (en) | 2011-01-31 | 2018-10-23 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
HUE058753T2 (hu) | 2011-01-31 | 2022-09-28 | Avalyn Pharma Inc | Aeroszol formájú pirfenidon- és piridon-analóg vegyületek és alkalmazásaik |
MX2011007675A (es) | 2011-07-19 | 2012-07-11 | Cell Therapy And Technology S A De C V | Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas. |
MX346763B (es) * | 2012-03-28 | 2017-03-31 | Cell Therapy And Tech S A De C V | Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné. |
MX356551B (es) | 2012-08-23 | 2018-06-04 | Grupo Medifarma S A De C V Star | Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné. |
AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
AU2015204558B2 (en) | 2014-01-10 | 2020-04-30 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
MX2016012808A (es) | 2014-04-02 | 2017-01-05 | Intermune Inc | Piridinonas anti-fibroticas. |
MX366086B (es) | 2017-08-15 | 2019-06-27 | Cell Therapy And Tech S A De C V | Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel. |
Family Cites Families (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL7317316A (es) | 1972-12-18 | 1974-06-20 | ||
US3839346A (en) | 1972-12-18 | 1974-10-01 | Affiliated Med Res | N-substituted pyridone and general method for preparing pyridones |
US4042699A (en) | 1972-12-18 | 1977-08-16 | Affiliated Medical Research, Inc. | Method for reducing serum glucose levels |
CA1049411A (en) | 1972-12-18 | 1979-02-27 | Affiliated Medical Research | N-substituted pyridone and general method for preparing pyridones |
US4052509A (en) | 1972-12-18 | 1977-10-04 | Affiliated Medical Research, Inc. | Method for reducing serum uric acid levels |
ZA757570B (en) * | 1974-12-09 | 1977-07-27 | Affiliated Med Res | A useful n-substituted pyridone |
US4105782A (en) | 1975-03-07 | 1978-08-08 | Yu Ruey J | Treatment of acne and dandruff |
JPS51128438A (en) | 1975-04-26 | 1976-11-09 | Yamanouchi Pharmaceut Co Ltd | An antibacterial drug against fish diseases |
SE430609B (sv) | 1976-12-21 | 1983-11-28 | Sca Development Ab | Sett att ur cellulosaderivat framstella absorberande material |
US4376118A (en) * | 1980-10-06 | 1983-03-08 | Miles Laboratories, Inc. | Stable nonaqueous solution of tetracycline salt |
JPS60214732A (ja) * | 1984-04-05 | 1985-10-28 | Grelan Pharmaceut Co Ltd | 外用貼付剤 |
JP2618256B2 (ja) * | 1988-03-31 | 1997-06-11 | ポーラ化成工業株式会社 | 消炎鎮痛外用剤 |
US5716632A (en) * | 1989-11-22 | 1998-02-10 | Margolin; Solomon B. | Compositions and methods for reparation and prevention of fibrotic lesions |
US5310562A (en) * | 1989-11-22 | 1994-05-10 | Margolin Solomon B | Composition and method for reparation and prevention of fibrotic lesions |
US5009895A (en) | 1990-02-02 | 1991-04-23 | Merck & Co., Inc. | Sustained release with high and low viscosity HPMC |
EP0702551B1 (en) | 1993-05-07 | 2002-09-25 | MARGOLIN, Solomon B. | Compositions and methods for reparation and prevention of fibrotic lesions |
US5436241A (en) * | 1994-01-14 | 1995-07-25 | Bristol-Myers Squibb Company | Topical anti-inflammatory compositions containing piroxicam |
AU709474B2 (en) * | 1995-12-21 | 1999-08-26 | Zoetis Services Llc | Injectable quinolone formulations |
DE19639816A1 (de) * | 1996-09-27 | 1998-04-02 | Hoechst Ag | Antimykotische Mittel mit hoher Wirkstofffreisetzung |
US5958420A (en) * | 1997-03-13 | 1999-09-28 | Nortrade Medical, Inc. | Treatment of burns, cuts, and abrasions of the skin |
US6365131B1 (en) * | 1997-10-31 | 2002-04-02 | J. B. Chemicals & Pharmaceuticals Ltd. | Pharmaceutical dental formulation for topical application of metronidazole benzoate, chlorhexidine gluconate and local anesthetic |
DE69917248T2 (de) | 1998-03-17 | 2005-05-04 | Margolin, Solomon B., Dallas | Topische antiseptische zusammensetzungen und verfahren |
GB9810949D0 (en) | 1998-05-22 | 1998-07-22 | Hewlett Healthcare Limited | Formulation |
EP1113798B1 (en) * | 1998-09-18 | 2003-01-02 | Mepha AG | Topical formulation of alkyl-, phenyl-pyridone |
US20020028784A1 (en) | 2000-03-10 | 2002-03-07 | Nest Gary Van | Methods of preventing and treating viral infections using immunomodulatory polynucleotide sequences |
IN191090B (es) * | 2000-08-29 | 2003-09-20 | Ranbanx Lab Ltd | |
JP4077320B2 (ja) | 2001-01-29 | 2008-04-16 | 塩野義製薬株式会社 | 5−メチル−1−フェニル−2−(1h)−ピリドンを有効成分として含有する医薬製剤 |
WO2003030720A2 (en) | 2001-10-09 | 2003-04-17 | The Children's Hospital Of Philadelphia | Materials and methods for preventing or reducing scar formation |
CH696420A5 (de) | 2002-09-13 | 2007-06-15 | Mepha Ag | Neue stabile Zubereitungen von Alkyl-, Phenyl-Pyridonen für topische Anwendung. |
JP4542743B2 (ja) * | 2002-12-26 | 2010-09-15 | Kdl株式会社 | ピリドン誘導体の溶液状医薬組成物 |
WO2004073713A1 (ja) * | 2003-02-21 | 2004-09-02 | Shionogi & Co., Ltd. | ピルフェニドンのゲル剤 |
EP1596883A1 (en) | 2003-02-28 | 2005-11-23 | Intermune, Inc. | Interferon drug therapy for the treatment of viral diseases and liver fibrosis |
AU2003225670A1 (en) | 2003-02-28 | 2004-09-28 | Intermune, Inc. | Interferon drug therapy for the treatment of viral diseases and liver fibrosis |
WO2004089283A2 (en) | 2003-04-04 | 2004-10-21 | Intermune, Inc. | Compositions and methods for treating viral infections |
EP1638625A4 (en) | 2003-05-23 | 2009-08-19 | David M Ott | ORGANOSOUFRES PROMEDICAMENTS FOR PREVENTING AND TREATING INFECTIOUS DISEASES AND A PATHOLOGICAL REACTION OF THE IMMUNE SYSTEM |
US20080025986A1 (en) | 2003-06-06 | 2008-01-31 | Ozes Osman N | Methods of Treating Tnf-Mediated Disorders |
AU2004281780B2 (en) | 2003-10-14 | 2009-03-19 | F. Hoffmann-La Roche Ltd | Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication |
US7491794B2 (en) | 2003-10-14 | 2009-02-17 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
US7407973B2 (en) | 2003-10-24 | 2008-08-05 | Intermune, Inc. | Use of pirfenidone in therapeutic regimens |
WO2005067454A2 (en) | 2003-12-23 | 2005-07-28 | Valeant Pharmaceuticals North America | Combination therapy for treating hepatitis c virus infection |
CN100542532C (zh) | 2004-05-24 | 2009-09-23 | 上海睿星基因技术有限公司 | 吡非尼酮在制备治疗肝损伤坏死和急性肺损伤的药物中的用途 |
US20060051339A1 (en) | 2004-09-08 | 2006-03-09 | Sivak Hannah N | Composition for treatment of oily skin and acne prevention and methods of making and using same |
US20060115503A1 (en) | 2004-11-30 | 2006-06-01 | Goyal Muna C | Composition, system and method for treatment of skin |
WO2006122154A2 (en) | 2005-05-10 | 2006-11-16 | Intermune, Inc. | Pyridone derivatives for modulating stress-activated protein kinase system |
EP2305695A3 (en) | 2005-07-25 | 2011-07-27 | Intermune, Inc. | Macrocyclic inhibitors of Hepatitis C virus replication |
NZ591443A (en) | 2005-09-22 | 2013-04-26 | Intermune Inc | Granule formation of pirfenidone and pharmaceutically acceptable excipients |
EP1960405A2 (en) | 2005-11-23 | 2008-08-27 | Intermune, Inc. | Method of modulating stress-activated protein kinase system |
EP1973525B1 (en) * | 2005-12-05 | 2014-04-30 | RBA Pharma Inc. | Emulsion-containing medical articles |
CN101088557A (zh) | 2006-06-12 | 2007-12-19 | 天津市扶素生物技术有限公司 | 用于预防或治疗hiv感染的药用组合物及其应用 |
AU2008216382A1 (en) | 2007-02-12 | 2008-08-21 | Array Biopharma, Inc. | Novel inhibitors hepatitis C virus replication |
WO2008107873A1 (en) | 2007-03-02 | 2008-09-12 | Yeda Res & Dev | Mercaptopurine derivatives as anticancer agents |
US20080287508A1 (en) | 2007-05-18 | 2008-11-20 | Intermune, Inc. | Altering pharmacokinetics of pirfenidone therapy |
KR101767849B1 (ko) | 2007-06-20 | 2017-08-11 | 오스펙스 파마슈티칼스, 인코포레이티드 | 섬유증 저해제로서의 치환된 n-아릴 피리디논 |
MX2007009796A (es) | 2007-08-14 | 2009-02-25 | Cell Therapy And Technology S | Gel conteniendo pirfenidona. |
US20090137354A1 (en) | 2007-11-27 | 2009-05-28 | Shimano Inc. | Bicycle rear derailleur |
JP2011506446A (ja) | 2007-12-11 | 2011-03-03 | コーダ セラピューティクス, インコーポレイテッド | 損傷した創傷治癒組成物および治療 |
US20100256031A1 (en) | 2008-10-10 | 2010-10-07 | Jeffrey Wu | Shine control cleanser |
AR075584A1 (es) | 2009-02-27 | 2011-04-20 | Intermune Inc | COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO. |
CN101972236A (zh) | 2010-10-13 | 2011-02-16 | 北京诚创康韵医药科技有限公司 | 一种含吡非尼酮的缓释制剂 |
CN101972225A (zh) | 2010-10-13 | 2011-02-16 | 北京诚创康韵医药科技有限公司 | 一种含吡非尼酮的凝胶组合物 |
HUE058753T2 (hu) | 2011-01-31 | 2022-09-28 | Avalyn Pharma Inc | Aeroszol formájú pirfenidon- és piridon-analóg vegyületek és alkalmazásaik |
EP2675449B1 (en) | 2011-02-15 | 2019-04-24 | Aclaris Therapeutics, Inc. | Pharmaceutical cream compositions of oxymetazoline for treating symptoms of rosacea |
CN102670600A (zh) | 2011-03-12 | 2012-09-19 | 赵海静 | 一种抑制瘢痕和促进创口愈合的医药产品,其制备方法和应用 |
CN102670632A (zh) | 2011-03-12 | 2012-09-19 | 赵海静 | 吡非尼酮在抑制皮肤瘢痕形成的医药用途 |
US9241921B2 (en) | 2011-05-02 | 2016-01-26 | Pankaj Modi | Photosensitizer composition for treating skin disorders |
MX2011007675A (es) | 2011-07-19 | 2012-07-11 | Cell Therapy And Technology S A De C V | Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas. |
CN102488660A (zh) | 2011-12-15 | 2012-06-13 | 西安天一秦昆制药有限责任公司 | 一种含吡非尼酮的缓释微丸 |
MX346763B (es) | 2012-03-28 | 2017-03-31 | Cell Therapy And Tech S A De C V | Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné. |
WO2013181691A1 (en) | 2012-06-04 | 2013-12-12 | The Macfarlane Burnet Institute For Medical Research And Public Health Ltd | A method of treatment and compositions useful therefor, screening and prognostic agents and uses therefor |
JP2015519400A (ja) | 2012-06-12 | 2015-07-09 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Hcv感染症を治療するための治療剤の組合せ |
MX356551B (es) | 2012-08-23 | 2018-06-04 | Grupo Medifarma S A De C V Star | Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné. |
CA2819967C (en) | 2012-08-31 | 2016-03-22 | Intermune, Inc. | Use of pirfenidone concomitantly with ciprofloxacin |
AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
US9156896B2 (en) | 2013-03-15 | 2015-10-13 | Coda Therapeutics, Inc. | Wound healing compositions and treatments |
AU2014233362A1 (en) | 2013-03-15 | 2015-10-01 | Medicis Pharmaceutical Corporation | Topical compositions of flunisolide and methods of treatment |
MX352342B (es) | 2013-07-12 | 2017-11-22 | Moleculas Naturales S A De C V Star | Un procedimiento para fabricar un complejo mejorado de cloruro de bencetonio-dialil oxido de disulfuro modificado, el complejo obtenido y sus usos. |
CN103550242B (zh) | 2013-11-22 | 2015-07-15 | 四川国康药业有限公司 | 一种治疗肝纤维化的药物组合物及其制备方法 |
GB201508419D0 (en) | 2015-05-15 | 2015-07-01 | Cambridge Entpr Ltd | Detection of T cell exhaustion or lack of T cell costimulation and uses thereof |
WO2017104725A1 (ja) | 2015-12-16 | 2017-06-22 | 第一三共株式会社 | 創傷治療剤 |
JOP20170113B1 (ar) | 2016-05-09 | 2023-03-28 | Bayer Pharma AG | مركبات 5، 6، 7، 8-رباعي هيدرو [1، 2، 4] تريازولو [4، 3-أ] بيريدين 3(2h)-ون مستبدلة ومركبات 2، 5، 6، 7-رباعي هيدرو-3h-بيرولو [2، 1-ج] [1، 2، 4] تريازول-3-ون واستخداماتها |
MX364040B (es) | 2016-11-11 | 2019-04-11 | Cell Therapy And Tech S A De C V | Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash). |
TWI770157B (zh) | 2017-04-10 | 2022-07-11 | 德商拜耳廠股份有限公司 | 經取代之n-芳基乙基-2-胺基喹啉-4-甲醯胺及其用途 |
MX366086B (es) | 2017-08-15 | 2019-06-27 | Cell Therapy And Tech S A De C V | Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel. |
MX368750B (es) | 2018-08-31 | 2019-10-15 | Cell Therapy And Tech S A De C V | Composiciones farmaceuticas semisolidas de base oleosa conteniendo pirfenidona para su aplicacion en la reparacion tisular. |
KR20230038644A (ko) | 2020-04-14 | 2023-03-21 | 엑스칼리버 파마슈티컬즈, 인크. | 코로나바이러스 치료를 위한 피르페니돈 |
-
2007
- 2007-08-14 MX MX2007009796A patent/MX2007009796A/es active IP Right Grant
-
2008
- 2008-08-14 CA CA2696335A patent/CA2696335C/en active Active
- 2008-08-14 SG SG2012060505A patent/SG183732A1/en unknown
- 2008-08-14 US US12/673,304 patent/US8492412B2/en active Active
- 2008-08-14 WO PCT/MX2008/000107 patent/WO2009022899A1/es active Application Filing
- 2008-08-14 EP EP08827482.4A patent/EP2177220B1/en active Active
- 2008-08-14 KR KR1020107003346A patent/KR101235968B1/ko active IP Right Grant
- 2008-08-14 BR BRPI0815203A patent/BRPI0815203B8/pt active IP Right Grant
- 2008-08-14 CN CN201510091398.9A patent/CN104771355A/zh active Pending
- 2008-08-14 CN CN200880103142A patent/CN101808641A/zh active Pending
- 2008-08-14 JP JP2010520954A patent/JP5542053B2/ja active Active
-
2010
- 2010-02-08 ZA ZA2010/00918A patent/ZA201000918B/en unknown
- 2010-02-11 CO CO10015040A patent/CO6180448A2/es active IP Right Grant
- 2010-02-12 EC EC2010009960A patent/ECSP109960A/es unknown
- 2010-10-28 HK HK15112082.7A patent/HK1211464A1/xx unknown
-
2013
- 2013-05-14 US US13/893,626 patent/US20130245073A1/en not_active Abandoned
-
2017
- 2017-02-17 US US15/435,494 patent/US10376500B2/en active Active
-
2019
- 2019-06-24 US US16/450,150 patent/US11083719B2/en active Active
-
2021
- 2021-07-30 US US17/390,368 patent/US11779574B2/en active Active
-
2023
- 2023-08-30 US US18/458,390 patent/US20240238262A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2010536747A (ja) | 2010-12-02 |
SG183732A1 (en) | 2012-09-27 |
JP5542053B2 (ja) | 2014-07-09 |
EP2177220A4 (en) | 2013-09-11 |
US10376500B2 (en) | 2019-08-13 |
CA2696335C (en) | 2014-03-04 |
US20200016138A1 (en) | 2020-01-16 |
BRPI0815203A2 (pt) | 2017-03-28 |
MX2007009796A (es) | 2009-02-25 |
US11779574B2 (en) | 2023-10-10 |
US20170216268A1 (en) | 2017-08-03 |
ECSP109960A (es) | 2010-04-30 |
WO2009022899A1 (es) | 2009-02-19 |
US20240238262A1 (en) | 2024-07-18 |
US20110224265A1 (en) | 2011-09-15 |
ZA201000918B (en) | 2011-04-28 |
HK1211464A1 (en) | 2016-05-27 |
CA2696335A1 (en) | 2009-02-19 |
KR20100040319A (ko) | 2010-04-19 |
WO2009022899A8 (es) | 2009-09-11 |
EP2177220B1 (en) | 2019-05-29 |
BRPI0815203B1 (pt) | 2020-05-05 |
US20220016096A1 (en) | 2022-01-20 |
EP2177220A1 (en) | 2010-04-21 |
US8492412B2 (en) | 2013-07-23 |
US20130245073A1 (en) | 2013-09-19 |
US11083719B2 (en) | 2021-08-10 |
BRPI0815203B8 (pt) | 2021-05-25 |
CN104771355A (zh) | 2015-07-15 |
KR101235968B1 (ko) | 2013-02-21 |
CN101808641A (zh) | 2010-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6180448A2 (es) | Gel conteniendo pirfenidona | |
ES2625747T3 (es) | Composición para limpieza personal que comprende agentes gelificantes y de formación de espuma para la impregnación de tejido | |
ES2567707T3 (es) | Cosmético protector solar de tipo emulsión de agua en aceite | |
BR0212378A (pt) | Inibidores de 17beta-hidroxiesteróide desidrogenase tipo 3 para o tratamento de doenças dependentes de androgênio | |
CU20190005A7 (es) | Goma de mascar administrable oralmente o formulaciones acuosas que comprenden un agente farmacéutico | |
PE20230466A1 (es) | N4-hidroxicitidina y derivados y usos antivirales relacionados con los mismos | |
BRPI0502145A (pt) | enxaguatório para prevenção e tratamento da halitose | |
PE20080374A1 (es) | Composiciones farmaceuticas de ropinirol | |
GT200000038A (es) | Inhibidores de la sorbitol deshidrogenasa. | |
AR106776A1 (es) | Composiciones de cuidado oral | |
BRPI0709581A8 (pt) | compostos de bicicloeteroarila como moduladores de px27 e seu uso | |
DE60131088D1 (de) | Gelierende wässrige pharmazeutische zusammensetzungen | |
GT200900329A (es) | Desodorante basado en propilenglicol/glicerina | |
AR036248A1 (es) | Derivados de 2h-piridazin-3-ona, composiciones farmaceuticas que los contienen y un proceso para la preparacion de dichos derivados y el uso de dichos derivados para la preparacion de una composicion farmaceutica | |
AR077138A1 (es) | Composiciones farmaceuticas utiles para tratar el vhc | |
BRPI0415953B8 (pt) | formulação de dosagem de liberação controlada e conjunto de formas de dosagem de liberação controlada | |
CL2009000625A1 (es) | Composicion farmaceutica que comprende a)un primer poliol seleccionado de manitol, sorbitol o una combinacion de ambos, b)segundo poliol seleccionado de propilenglicol, glicerina o una combinacion de ambas, c)complejo de borato en un 0,5% p/v de la composicion total, d)preservante, e)agua; util para el tratamiento del ojo. | |
CO6251360A2 (es) | Bromhidrato de bupropion y aplicaciones terapeuticas | |
AR077139A1 (es) | Composiciones farmaceuticas utiles para tratar el vch | |
EA201001324A1 (ru) | Гель, обладающий противовоспалительным и противоаллергическим действием | |
BR112014002594A2 (pt) | uso de diésteres de isossorbida como espessantes | |
US20120202767A1 (en) | Hyaluronic acid based mucoadhesive therapeutic composition for the prevention and treatment of epithelial and mucosal lesions of the human body | |
CO6351721A2 (es) | Uso de dronedarona para la preparacion de un medicamento para la prevencion de ictus o ataque isquemico transitorio | |
AR083803A1 (es) | Composiciones orales que contienen microagregados | |
JP5669522B2 (ja) | フォーマー容器入り液体洗浄剤組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Application granted |